PFE · 10-Q · 2026Q3 · Full report

Share Repurchase Program

PFIZER INC · 2026-11-03 · Importance 26 · Surprise 24

Pfizer had $3.3 billion remaining under its share-purchase authorization as of September 27, 2026. The company made no share repurchases in the first nine months of 2026. Pfizer’s capital allocation framework says share repurchases could resume after balance-sheet deleveraging.

Key facts

• As of September 27, 2026, Pfizer had $3.3 billion remaining under its share-purchase authorization and made no repurchases in the first nine months of 2026. source